Soleno Therapeutics, Inc.
SLNO
$65.60
$2.864.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 159.33% | 245.36% | 801.04% | 1,382.73% | 243.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.92% | 85.39% | 358.25% | 747.51% | 179.55% |
| Operating Income | 76.65% | -85.39% | -358.25% | -747.51% | -179.55% |
| Income Before Tax | 78.46% | -104.57% | -395.59% | -605.42% | -157.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 78.46% | -104.57% | -395.59% | -605.42% | -157.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.46% | -104.57% | -395.59% | -605.42% | -157.86% |
| EBIT | 76.65% | -85.39% | -358.25% | -747.51% | -179.55% |
| EBITDA | 78.35% | -87.18% | -372.33% | -788.68% | -190.72% |
| EPS Basic | 83.51% | -60.39% | -288.57% | -92.64% | 30.43% |
| Normalized Basic EPS | 86.33% | -52.40% | -327.13% | -110.21% | 33.16% |
| EPS Diluted | 83.51% | -60.39% | -288.57% | -92.64% | 30.43% |
| Normalized Diluted EPS | 86.33% | -52.40% | -327.13% | -110.21% | 33.16% |
| Average Basic Shares Outstanding | 30.68% | 27.54% | 27.53% | 266.18% | 270.62% |
| Average Diluted Shares Outstanding | 30.68% | 27.54% | 27.53% | 266.18% | 270.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |